"The U.S. Food and Drug Administration today approved Ragwitek, the first allergen extract administered under the tongue (sublingually) to treat short ragweed pollen induced allergic rhinitis (hay fever), with or without conjunctivitis (eye inflam"...
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Ocular Adverse Reactions
The most frequent ocular adverse reactions, occurring in < 4% of LASTACAFT™ (alcaftadine ophthalmic solution) -treated eyes, were eye irritation, burning and/or stinging upon instillation, eye redness and eye pruritus.
Non-ocular Adverse Reactions
The most frequent non-ocular adverse reactions, occurring in < 3% of subjects with LASTACAFT™ (alcaftadine ophthalmic solution) -treated eyes, were nasopharyngitis, headache and influenza. Some of these events were similar to the underlying disease being studied.
Last reviewed on RxList: 8/20/2010
This monograph has been modified to include the generic and brand name in many instances.
Additional Lastacaft Information
Lastacaft - User Reviews
Lastacaft User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.